Lo Giudice, Maria
Cocco, Antoniangela
Reggiardo, Giorgio
Lalli, Stefania
Albanese, Alberto http://orcid.org/0000-0002-5864-0006
Funding for this research was provided by:
Horizon 2020 Framework Programme (755094)
Università Cattolica del Sacro Cuore
Article History
Accepted: 29 October 2023
First Online: 16 November 2023
Declarations
:
: Open access funding provided by Università Cattolica del Sacro Cuore within the CRUI-CARE Agreement. This article was funded by the European Union’s Horizon 2020 research and innovation program under grant agreement no. 755094 to Alberto Albanese.
: Alberto Albanese is the Principal Investigator of the project “Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS)” funded by the European Union’s Horizon 2020 research and innovation program. Maria Lo Giudice and Antoniangela Cocco are supported by the same project. Giorgio Reggiardo and Stefania Lalli have no conflicts of interest that are directly relevant to the content of this article.
: No approval was required by the ethics committee as this study is based on a literature review only.
: Not applicable.
: Not applicable.
: Data are available from published sources and online repositories, as referenced. Data extraction tables are available as an online supplement.
: Not applicable.
: MLG researched data for the article and drafted the manuscript. GR performed a statistical reassessment and contributed to the writing of the manuscript. AC and SL reviewed the manuscript. AA contributed to the concept, design, and critical revision of the manuscript. All authors read and approved the final manuscript.